| Aurobindo Pharma Ltd | Industry : (Pharmaceuticals) | |
|---|---|---|
|
BSE Code : 524804 |
NSE Symbol : AUROPHARMA |
P/E(TTM) : 38.02 |
|
ISIN Demat : INE406A01037 |
Div & Yield% : 0.25 |
EPS(TTM) : 41.81 |
|
Book Value(₹) : 391.14 |
Market Cap(₹Cr) : 92,318.42 |
Face Value(₹) : 1.00 |
| Particulars | Dec '26 | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|---|
| INCOME : | |||||
| Sales Turnover | - | - | - | - | - |
| Excise Duty | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Sales | 11,171.72 | 10,933.30 | 10,645.64 | 8,457.00 | 11,287.14 |
| Other Income | 587.53 | 328.12 | 670.10 | 443.92 | 670.99 |
| Stock Adjustments | -46.55 | 67.66 | 116.23 | 263.95 | -45.51 |
| Total Income | 11,712.70 | 11,329.08 | 11,431.97 | 9,164.87 | 11,912.62 |
| EXPENDITURE : | |||||
| Raw Materials | 5,311.58 | 5,675.34 | 5,964.48 | 4,755.95 | 5,800.74 |
| Power and Fuel Cost | 174.82 | 185.59 | 191.58 | 167.86 | 477.99 |
| Other Manufacturing Expenses | 421.52 | 426.63 | 414.51 | 328.42 | 705.68 |
| Selling and Administration Expenses | 873.42 | 960.27 | 822.21 | 939.38 | 1,009.36 |
| Miscellaneous Expenses | 108.12 | 132.49 | 164.49 | 148.96 | 249.13 |
| Employee Benefit Expenses | 1,161.15 | 1,063.07 | 980.56 | 890.53 | 1,600.04 |
| Less: Preoperative Expenditure | - | - | - | - | - |
| Total Expenses | - | - | - | - | - |
| Operating Profit | 3,662.09 | 2,885.69 | 2,894.14 | 1,933.77 | 2,069.68 |
| Interest | 213.15 | 230.04 | 182.60 | 74.58 | 16.94 |
| Gross Profit | 3,448.94 | 2,655.65 | 2,711.54 | 1,859.19 | 2,052.74 |
| Depreciation | 285.36 | 297.20 | 254.58 | 243.26 | 415.26 |
| Profit Before Tax | 3,163.58 | 2,358.45 | 2,456.96 | 1,615.93 | 1,637.48 |
| Current Tax | 746.82 | 627.37 | 598.08 | 412.16 | 379.70 |
| Fringe Benefit tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax | 1.96 | -15.71 | -95.26 | -23.34 | -196.93 |
| Reported Net Profit | 2,414.80 | 1,746.79 | 1,954.14 | 1,227.11 | 1,454.71 |
| Extraordinary Items | -11.93 | 9.46 | 3.28 | 9.94 | -81.27 |
| Adjusted Net Profit | 2,426.73 | 1,737.33 | 1,950.86 | 1,217.17 | 1,535.98 |
| Adjustment below Net Profit | 1.08 | -5.26 | -1.69 | 8.28 | 1.69 |
| Profit/Loss Balance carried down | 20,090.40 | 18,348.87 | 16,660.08 | 15,864.14 | 14,671.41 |
| Statutory Appropriations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Appropriations | 232.30 | 0.00 | 263.66 | 439.45 | 263.67 |
| P & L Balance carried down | 22,273.98 | 20,090.40 | 18,348.87 | 16,660.08 | 15,864.14 |
| Dividend | 232.30 | 0.00 | 263.66 | 439.45 | 0.00 |
| Preference Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity Dividend (%) | 400.00 | 0.00 | 450.00 | 750.00 | 900.00 |
| Dividend Per Share(Rs) | 4.00 | 0.00 | 4.50 | 7.50 | 9.00 |
| Earnings Per Share-Unit Curr | 41.58 | 30.08 | 33.35 | 20.94 | 24.83 |
| Earnings Per Share(Adj)-Unit Curr | - | - | - | - | - |
| Book Value | 391.14 | 353.55 | 336.62 | 307.80 | 292.15 |
| Book Value(Adj)-Unit Curr | 391.14 | 353.55 | 336.62 | 307.80 | 292.15 |
